Expert consensus on clinical practice update on HF
The most recent guidelines on heart failure by the ESC have been published in 2016. Since then, new data from major trials have become available (SGLT2 inhibitors in type 2 diabetes, MitraClip for functional mitral regurgitation, AF ablation in HF, tafamidis in cardiac transthyretin amyloidosis, rivaroxaban in HF, ICD’s in non-ischemic HF, and telemedicine for HF) and results from smaller trials and meta-analyses in other areas have been published. It will be 2 years before the 2021 ESC guidelines on HF will be released. Therefore, recent developments on HF need to be reviewed and summarized. The Heart Failure Association of the ESC has gathered in Jan 2019 in Frankfurt and has come up with consensus recommendations.
This report describes these consensus recommendations, supporting evidence, some practical comments and directions for future development on pharmacotherapy, device-based therapies, and general care relevant to the management of HF. It is not intended as a guideline update, nor a position statement.